Haloperidol-induced tardive dyskinesia in monkeys.
In three cebus monkeys the chronic daily administration of haloperidol (0.5 mg/kg/day orally) created sedation and parkinsonism during the first 5-7 weeks. Later the animals developed signs reminiscent of acute dystonia, as seen in the clinic during treatment with neuroleptics. These signs were dose-dependent and in extreme cases included widespread tonic and clonic seizures. After 3 and 12 months, respectively, two of the cebus monkeys developed buccolingual signs (grimacing and tongue protrusion), similar to tardive dyskinesia in the clinic. The tardive dyskinesia symptoms were reduced in a dose-dependent manner after each haloperidol administration, being most pronounced in the morning before haloperidol was given. Biperiden reduced acute dystonia but reinstated signs of tardive dyskinesia, which had been abolished by haloperidol. It is suggested that cebus monkeys may provide a useful animal model for the study of neurologic long-term complications from neuroleptic drugs.
D000818:Animals; D004195:Disease Models, Animal; D004409:Dyskinesia, Drug-Induced / Q000209:etiology*; D005260:Female; D006220:Haloperidol / Q000009:adverse effects*; D000882:Haplorhini; D008252:Macaca fascicularis; D008297:Male; D009069:Movement Disorders / Q000139:chemically induced; D009129:Muscle Tonus / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D013997:Time Factors
D006220:Haloperidol